PubHawk
August 1998 PMID 9718377

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

A Besarab, W K Bolton, J K Browne, J C Egrie, A R Nissenson, D M Okamoto, S J Schwab, D A Goodkin

Full text PDF Download social card

Mentions

24
Peak: 4 in Jan 2019
across 5 sources since Feb 2016

Extended reach

32,580
potential audience

Total likes

59

Video views

3,741

Mentions per month

Feb 2016 – Apr 2024

Where it's discussed

  • Blogs11 articles
  • X / Twitter6 posts
  • News4 articles
  • YouTube2 videos
  • Bluesky1 posts

AI synopsis

What people are saying

The discussions reflect a balanced consideration of the article's findings, with users mentioning the 'Normal Hematocrit Study' and debates on treatments like Epoetin, using language that suggests a moderate level of engagement and acknowledgment of its implications for patient care.

AgreementModerate agreement

Most discussions acknowledge the study’s findings, suggesting a cautious acceptance of the results indicating higher risks with normal hematocrit levels.

InterestModerate interest

The discussions show moderate curiosity, referencing specific trials like the 'Normal Hematocrit Study' and debates around Epoetin use, indicating engagement with clinical implications.

EngagementModerate engagement

The remarks display some depth, including mentions of trial designs and related studies such as Beserab and TREAT, which demonstrates considered analysis.

ImpactModerate impact

Participants recognize the study’s significance, especially in the context of ESRD, cardiac conditions, and anemia treatment, indicating perceived influence on clinical practices.

Abstract in brief

  • The study compared the effects of maintaining a normal hematocrit level (around 42%) versus a lower level (around 30%) in patients with heart disease undergoing hemodialysis and treated with epoetin.
  • Results showed that patients with normal hematocrit had a higher risk of death or nonfatal myocardial infarction, leading to early stopping of the study despite the difference not being statistically significant.
  • Increasing hematocrit was associated with decreased mortality rates but also led to more complications such as reduced dialysis adequacy and increased use of intravenous iron.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Tejas Desai, MD, MBA
@nephondemand · X

• Normal Hematocrit Study https://t.co/ycxCqMaxst Randomized non-placebo trial of Epoetin in dialysis

Jan 16, 2019 · 4 likes · 3 shares · 11,982 followers View post →
KIReports
@KIReports · X

ESKD, CVD and EPO (c.1998) 1233 patients with ESRD and CHF or CAD.

Oct 19, 2021 · 2 likes · 13,760 followers View post →
Vineet Behera
@BeheraVineet · X

RT @nephondemand: • Normal Hematocrit Study https://t.co/ycxCqMaxst Randomized non-placebo trial of Epoetin in dialysis

Jan 17, 2019 · 3 shares · 2,141 followers View post →
Dr Theepa N.M.R
@TNesam · X

RT @nephondemand: • Normal Hematocrit Study https://t.co/ycxCqMaxst Randomized non-placebo trial of Epoetin in dialysis

Jan 27, 2019 · 3 shares · 697 followers View post →
pharmacist
@pharmacistKAMO · X

血液透析およびエポエチンを受けている心臓病患者における低ヘマトクリット値と比較した正常の効果 PMID: 9718377 https://t.co/v3HKhIrS3E

Aug 15, 2023 · 182 followers View post →
madree
@madrees007 · X

RT @nephondemand: • Normal Hematocrit Study https://t.co/ycxCqMaxst Randomized non-placebo trial of Epoetin in dialysis

Jan 21, 2019 · 3 shares · 53 followers View post →

All mentions

pharmacist
@pharmacistKAMO · X

血液透析およびエポエチンを受けている心臓病患者における低ヘマトクリット値と比較した正常の効果 PMID: 9718377 https://t.co/v3HKhIrS3E

Aug 15, 2023 · 182 followers View post →
KIReports
@KIReports · X

ESKD, CVD and EPO (c.1998) 1233 patients with ESRD and CHF or CAD.

Oct 19, 2021 · 2 likes · 13,760 followers View post →
Dr Theepa N.M.R
@TNesam · X

RT @nephondemand: • Normal Hematocrit Study https://t.co/ycxCqMaxst Randomized non-placebo trial of Epoetin in dialysis

Jan 27, 2019 · 3 shares · 697 followers View post →
madree
@madrees007 · X

RT @nephondemand: • Normal Hematocrit Study https://t.co/ycxCqMaxst Randomized non-placebo trial of Epoetin in dialysis

Jan 21, 2019 · 3 shares · 53 followers View post →
Vineet Behera
@BeheraVineet · X

RT @nephondemand: • Normal Hematocrit Study https://t.co/ycxCqMaxst Randomized non-placebo trial of Epoetin in dialysis

Jan 17, 2019 · 3 shares · 2,141 followers View post →
Tejas Desai, MD, MBA
@nephondemand · X

• Normal Hematocrit Study https://t.co/ycxCqMaxst Randomized non-placebo trial of Epoetin in dialysis

Jan 16, 2019 · 4 likes · 3 shares · 11,982 followers View post →
Joel Topf
@kidneyboy.bsky.social · Bluesky

#NephJCclassics 2 ESA anemia classics: Beserab and TREAT http://www.nejm.org/doi/full/10.1056/NEJMoa0907845 http://www.nejm.org/doi/full/10.1056/NEJM199808273390903

Feb 16, 2016 View post →